Pamela Kunz
Director, Center for Gastrointestinal Cancers · Smilow Cancer Hospital and Yale Cancer Center
Credentials: · · · ·
History
- Present
Center for Gastrointestinal Cancers · Smilow Cancer Hospital and Yale Cancer Center
- Present
GI Medical Oncology Division · Yale Cancer Center
Present
- 2023–2026
Chief Resident2026–Present
2007–2008- 2001–2004
Chief ResidentUntil 2005
- 1993–1997
Research
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
New England Journal of Medicine · 2017 · 2,601 citations
Organoid Modeling of the Tumor Immune Microenvironment
Cell · 2018 · 1,265 citations
The Lancet Oncology · 2021 · 510 citations
25 papers
- JS
19 papers
17 papers
16 papers
15 papers
15 papers
12 papers
10 papers
Clinical trials
- 2013–2026
Principal investigator · Active not recruiting · Phase 2
ECOG-ACRIN Cancer Research Group
- 2009–2010
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Principal investigator · Terminated · Phase 2
Pamela L. Kunz
- 2009–2017
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Principal investigator · Completed · Phase 2
Stanford University
- 2006–2012
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Principal investigator · Completed · Phase 2
Pamela L. Kunz